Invokana Lawsuit Plaintiffs Note FDA Adverse Event Reports And Warning Label Changes For Diabetes Drug

March 25, 2016 – – TheProductLawyers.com reports on a public safety communication which was issued by the U.S. Food and Drug Administration on December 4th of 2015. The agency’s announcement indicated new requirements for the warning label on new-generation, type-2 diabetes drug Invokana, which will have to be made by the product’s manufacturer, Johnson & Johnson division Janssen Pharmaceuticals.

The FDA announcement closely followed a large number of adverse event reports which the agency received in reference to health problems developing among patients using Invokana and other similar SGLT2 class inhibitor drugs. The FDA’s warning statement specifically addresses diabetic ketoacidosis, a condition in which the body develops a surplus of toxic acid in its bloodstream. This medical condition can be a fatal condition, and, therefore, needs to be taken very seriously. The FDA has asked that all patients currently taking SGLT2 inhibitor drugs watch carefully for symptoms of developing ketoacidosis, which can include nausea and vomiting, frequent urination, excess fatigue, abdominal pain, or trouble breathing.

Because it has been reported that the FDA is now closely observing a potential connection between diabetic ketoacidosis and Invokana, the public has also become concerned. The links reported from Invokana show diabetic ketoacidosis which has occurred without significantly heightened blood sugar levels (as is typical), therefore, it can be more difficult to diagnose. Patients that go undiagnosed can become comatose or die. The FDA discussed their adverse event report findings, noting that, “All patients required hospitalization or treatment in an emergency department. In many cases, ketoacidosis was not immediately recognized because the blood glucose levels were below those typically expected for diabetic ketoacidosis. As a result, treatment of the ketoacidosis was delayed in some cases.”

The attorneys of Banville Law understand how concerning this information may be for patients currently depending upon Invokana or other SGLT2 class inhibitor drugs. They are dedicated to keeping the public informed about the latest updates concerning these potential links, and sponsor TheProductLawyers.com in order to do so. In addition, they are working to help ensure that patients who have taken Invokana or other SGLT2-class inhibitor drugs and who have suffered from adverse events will be provided with the opportunity to explore their legal rights in full. To help those wishing to pursue justice, the attorneys of Banville Law also currently offer free legal consultations. Patients who have been affected could be entitled to significant compensation gained through legal action.

To request further information, or to ask questions regarding Invokana lawsuits, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008892